News:
Salient Pharmaceuticals Meets Goals on Second Round Funding from Texas Emerging Technology Fund
HOUSTON, Texas -- Salient Pharmaceuticals Incorporated has announced the receipt of its second $1 million investment from the Texas Emerging Technology Fund (TETF). The investment is part of an overall $2 million commitment made by Texas Governor Perry and the TETF in 2009 to the Houston-based life sciences company. The… read full story »
Salient Pharmaceuticals Passes Milestone In Patient Enrollment of Phase II Trial
HOUSTON, Texas -- Salient Pharmaceuticals Incorporated, today announced the enrollment of the 20th patient in its Phase II cancer therapy-induced diarrhea (CTID) trial and the conclusion of the first in-study interim analysis studying the toxicity of its proprietary product, CASAD(TM). CASAD is being studied for use in treating CTID in… read full story »
Salient Pharmaceuticals Expansion of Scientific Advisory Board
HOUSTON, Texas -- Timothy D. Phillips, PhD, a professor at Texas A&M University and an internationally known expert in the world of food safety and mycotoxins, has joined Salient Pharmaceutical's Scientific Advisory Board. Salient Pharmaceuticals Incorporated is a Texas-based, life sciences company developing a proprietary compound intended for use in… read full story »
Salient Pharmaceuticals Expands Board of Directors
HOUSTON, Texas -- Salient Pharmaceuticals Incorporated, Texas-based life sciences company developing a proprietary compound intended for use in treating severe diarrhea associated with chemotherapy, chronic conditions, infectious diseases and other drug therapies, today announced two additions to its Board of Directors, Saurabh Biswas and Darrell Petty. "As we work to… read full story »
Gov. Perry Announces $2 Million Investment in Development, Commercialization of Cancer Treatment
Salient Pharmaceuticals treatment eases side effects of chemotherapy AUSTIN - Gov. Rick Perry today announced that the Texas Emerging Technology Fund will invest $2 million in Salient Pharmaceuticals Inc. of Houston for the commercialization of their CASAD therapy, used to prevent and treat some side effects of cancer therapy. "This… read full story »
Governor Perry and Texas ETF Fund Invest in Salient Pharmaceuticals
HOUSTON, Texas — Texas Governor Perry and the state's Emerging Technology Fund (ETF) today announced a $1 million investment in Houston-based Salient Pharmaceuticals Incorporated with a second $1 million investment contingent on the company meeting six key milestones. The investment will allow for the commercialization of a cancer therapy-induced diarrhea… read full story »
Salient Pharmaceuticals Exceeds Second Round Funding Goal
HOUSTON, Texas — Salient Pharmaceuticals Incorporated, a company developing a novel approach to preventing and/or treating severe acute and chronic diarrhea, today announced that it more than doubled its second round investment goal, much of it from previously committed investors. $1,160,000 was raised with approximately half coming from previous investors… read full story »
Salient Pharmaceuticals Expands Scientific Advisory Board
HOUSTON, Texas — Salient Pharmaceuticals Incorporated, announced today that the Company has added three internationally recognized experts to its Scientific Advisory Board, to advise on the development of its new product for severe diarrhea. Richard Scruggs, President and CEO of Salient Pharmaceuticals stated “These three men join our established board… read full story »
Salient Pharmaceuticals Announces Formation of Scientific Advisory Board for Strategic Vision
HOUSTON, Texas — Salient Pharmaceuticals Incorporated, a company developing a novel product for the prevention and/or treatment of severe diarrhea, today announced the establishment of the company’s Scientific Advisory Board. Chosen for their experience and reputation, the clinical, research, academic and business advisors will help guide the Company in the development… read full story »
Salient Pharmaceuticals Closes First Round of Angel Funding
HOUSTON, Texas — Salient Pharmaceuticals Incorporated, has today announced the successful completion of its first round of national funding. $475,000 was raised from investors in Texas, Washington and North Carolina, with approximately $250,000 coming from members of the Houston Angel Network. With the investment, the Company will finalize plans… read full story »
